Non-coding DNA Motifs for Latent HIV Reservoir Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV-1 latency, such as antiretroviral therapy and histone de-acetylase inhibitors, fail to effectively activate latent HIV-infected cells for immune-mediated killing, leading to incomplete reduction of the viral reservoir and potential disease progression.
Innovation Solution
Non-coding sequences of deoxyribonucleic acids with specific motifs (N1N2CGN3N4) are used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors to reactivate latent HIV-infected cells, enhancing immune recognition and destruction by stimulating natural killer cells and CD8+ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If latency reversing agents are used to reactivate latent HIV-infected cells, then immune recognition of infected cells is improved, but the risk of activating HIV-infected cells and causing disease progression increases
Solution Approach 1:
The patent applies local quality by differentiating between innate immune activation (desirable for killing infected cells) and adaptive immune activation (risky for disease progression). The non-coding DNA sequences specifically target and enhance innate immune cell functions (NK cells, macrophages, dendritic cells) while avoiding activation of adaptive immune responses that could harm the patient.
Solution Approach 2:
The non-coding DNA sequences act as intermediaries that bridge the gap between latent HIV reservoirs and the immune system. They stimulate innate immune cells to recognize and kill infected cells without directly activating the adaptive immune system, thus mediating a safe and effective immune response against latent HIV.
2Productivity
If combination antiretroviral therapy is used to suppress viral growth, then viral replication is reduced, but the viral reservoir is not eliminated and patients remain virus-free only during treatment
Solution Approach 1:
The patent applies preliminary action by using non-coding DNA sequences to pre-activate and expose latent HIV reservoirs before they can reactivate and cause disease progression. This preparatory step makes the hidden reservoir visible and vulnerable to immune attack, complementing the suppressive effect of antiretroviral therapy.
Solution Approach 2:
The combination of antiretroviral therapy (continuous viral suppression) and non-coding DNA sequences (continuous immune stimulation) creates a continuous dual-action treatment regimen that simultaneously suppresses active replication and eliminates latent reservoirs, providing ongoing protection against both forms of viral persistence.
3Reliability
If the immune system is activated to kill reactivated infected cells, then the viral reservoir reduction is improved, but the disease may progress due to activation of HIV-infected cells
Solution Approach 1:
The patent applies local quality by differentiating between innate immune activation (desirable for killing infected cells) and adaptive immune activation (risky for disease progression). The non-coding DNA sequences specifically target and enhance innate immune cell functions (NK cells, macrophages, dendritic cells) while avoiding activation of adaptive immune responses that could harm the patient.
Data Source
AI summary
The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.